VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Ongoing studies in CML: investigating asciminib toxicity and improving TFR rates

Michael Deininger, MD, PhD, The Medical College of Wisconsin, Milwaukee, WI, discusses current and future trials that he is excited to see the results of in the field of chronic myeloid leukemia (CML). Dr Deininger highlights a study investigating the toxicity of asciminib in patients with CML, as well as studies evaluating combinations of tyrosine kinase inhibitors (TKIs) and ruxolitinib to improve treatment-free remission (TFR) rates, and a study investigating the possibility of using asciminib in patients who have failed one TFR attempt. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Novartis, BMS, Incyte, Takeda, Blueprint, Cogent, CTI.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter